--- page 1 ---
1
Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Stock Exchange ”)
and Hong Kong Securities Clearing Company Limited ( “HKSCC ”) take no responsibility for the contents of this
announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability
whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this
announcement.
Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those
defined in the prospectus dated May 5, 2026 (the “Prospectus ”) of Metis TechBio Co., Ltd. (Ҧ (̏ԯ)΅Ϟ
ʮ̡) (the “Company ”).
This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer
by any person to acquire, purchase or subscribe for any of the securities of the Company. This announcement is not a
prospectus. Potential investors should read the Prospectus for detailed information about the Global Offering described
below before deciding whether or not to invest in the Offer Shares. Any investment decision in relation to the Offer
Shares should be taken solely in reliance on the information provided in the Prospectus.
This announcement does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale
of Offer Shares in any jurisdiction in which such offer, solicitation or sales would be unlawful. This announcement is
not for release, publication or distribution, directly or indirectly, in or into the United States or any other jurisdiction
where such distribution is prohibited by law, nor is this announcement an offer for sale or solicitation to purchase or
subscribe for securities in the United States or any other jurisdictions. The Offer Shares have not been and will not
be registered under the U.S. Securities Act or any state securities laws in the United States and may not be offered,
sold, pledged or transferred within the United States or to, or for the account or benefit of U.S. persons (as defined
in Regulation S under the U.S. Securities Act), except in transactions exempt from, or not subject to, the registration
requirements of the U.S. Securities Act. The Offer Shares are being offered and sold (1) solely to qualified institutional
buyers as defined in Rule 144A in reliance on Rule 144A or another exemption from, or in a transaction not subject
to, registration under the U.S. Securities Act and (2) outside the United States in offshore transactions in reliance on
Regulation S under the U.S. Securities Act and applicable laws of each jurisdiction where those offers and sales occur.
In connection with the Global Offering, CLSA Limited, as the stabilizing manager (the “Stabilizing Manager ”)
(or any person acting for it), on behalf of the Underwriters, may over-allocate or effect transactions with a view to
stabilizing or supporting the market price of the Shares at a level higher than that which might otherwise prevail for a
limited period after the Listing Date. However, there is no obligation on the Stabilizing Manager (or any person acting
for it) to conduct any such stabilizing action. Such stabilizing action, if taken, (a) will be conducted at the absolute
discretion of the Stabilizing Manager (or any person acting for it) and in what the Stabilizing Manager (or any person
acting for it) reasonably regards as the best interest of our Company, (b) may be discontinued at any time, and (c) is
required to be brought to an end within 30 days after the last day for lodging applications under the Hong Kong Public
Offering (which is Sunday, June 7, 2026). Such stabilization action, if taken, may be effected in all jurisdictions where
it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements,
including the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), as amended,
made under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).
Potential investors should be aware that no stabilizing action can be taken to support the price of the Shares for longer
than the stabilization period which begins on the Listing Date, and is expected to expire on Sunday, June 7, 2026, the
30th day after the last day for the lodging of applications under the Hong Kong Public Offering. After this date, when
no further stabilizing action may be taken, demand for the Shares, and therefore the price of the Shares, could fall.
The Hong Kong Offer Shares will be offered to the public in Hong Kong subject to the terms and conditions set out
in the Prospectus. The Hong Kong Offer Shares will not be offered to any person who is outside Hong Kong and/
or not resident in Hong Kong. Potential investors of the Offer Shares should note that the Joint Sponsors and the
Sponsor-Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to
terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence
of any of the events set out in the section headed “Underwriting {  Underwriting Arrangements and Expenses {  Hong
Kong Public Offering {  Grounds for Termination ” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time)
on the Listing Date (which is currently expected to be on Wednesday, May 13, 2026).


--- page 2 ---
2
Metis TechBio Co., Ltd.
Ҧ (̏ԯ)ʮ̡
(A joint stock company incorporated in the People ’s Republic of China with limited liability)
GLOBAL OFFERING
Number of Offer Shares under the Global
Offering
: 201,229,000 H Shares (subject to the
 Over-allotment Option)
Number of Hong Kong Offer Shares : 40,246,000 H Shares (as adjusted after
 reallocation)
Number of International Offer Shares : 160,983,000 H Shares (as adjusted after
 reallocation and subject to the
 Over-allotment Option)
Offer Price : HK$10.50 per H Share, plus brokerage
 of 1%, SFC transaction levy of 0.0027%,
 Stock Exchange trading fee of 0.00565%
 and Accounting and Financial Reporting
 Council transaction levy of 0.00015%
Nominal value : RMB0.10 per H Share
Stock code : 7666
Joint Sponsors
Overall Coordinators and Joint Global Coordinators
Joint Bookrunners and Joint Lead Managers


--- page 3 ---
3
METIS TECHBIO CO., LTD.
Ҧ (̏ԯ)ʮ̡
ANNOUNCEMENT OF ALLOTMENT RESULTS
Unless otherwise defined herein, capitalised terms used in this announcement shall have the same
meanings as those defined in the prospectus dated May 5, 2026 (the “Prospectus ”) issued by Metis
TechBio Co., Ltd. (Ҧ (̏ԯ)ʮ̡) (the “Company ”).
SUMMARY
Warning: In view of high concentration of shareholding in a small number of Shareholders,
Shareholders and prospective investors should be aware that the price of the H Shares
could move substantially even with a small number of H Shares traded and should exercise
extreme caution when dealing in the H Shares.
Company information
Stock code 7666
Stock short name METIS TECHBIO-P
Dealings commencement date 13 May 2026*
* see note at the end of the announcement
Price Information
Offer Price HK$10.50
Offer Shares and Share Capital
Number of Offer Shares (before exercise of the Over-
allotment Option)
201,229,000
Final Number of Offer Shares in Hong Kong Public Offering
(after reallocation)
40,246,000
Final Number of Offer Shares in International Offering
(after reallocation and before exercise of the Over-allotment
Option)
160,983,000
Number of issued shares upon Listing (before exercise of the
Over-allotment Option)
1,152,513,850


--- page 4 ---
4
Over-allocation
No. of Offer Shares over-allocated 30,184,000
Such over-allocation may be covered by exercising the Over-allotment Option or by making
purchases in the secondary market at prices that do not exceed the Offer Price or through
deferred delivery or a combination of these means. In the event the Over-allotment Option is
exercised, an announcement will be made on the Stock Exchange ’s website.
Proceeds
Gross proceeds (Note) HK$2,112.9 million
Less: Estimated listing expenses payable based on Offer Price HK$(120.2) million
Net proceeds HK$1,992.7 million
Note: Gross proceeds refer to the amount to which the issuer is entitled receive. For details of the use of proceeds,
please refer to the section headed “Future Plans and Use of Proceeds ” of the Prospectus. The Company will
adjust the allocation of the net proceeds from the exercise of the Over-allotment Option (if any) for the
purposes as set out in the section headed “Future Plans and Use of Proceeds ” of the Prospectus on a pro rata
basis.


--- page 5 ---
5
ALLOTMENT RESULTS DETAILS
HONG KONG PUBLIC OFFERING
No. of valid applications 383,309
No. of successful applications 65,740
Subscription level 6910.96 times
Claw-back triggered Yes
No. of Offer Shares initially available under the Hong Kong
Public Offering
10,061,500
No. of Offer Shares reallocated from the International
Offering (claw-back)
30,184,500
Final no. of Offer Shares under the Hong Kong Public
Offering (after reallocation)
40,246,000
% of Offer Shares under the Hong Kong Public Offering to
the Global Offering
20%
Note: For details of the final allocation of H Shares to the Hong Kong Public Offering, investors
can refer to www.eipo.com.hk/eIPOAllotment  to perform a search by identification number or
www.eipo.com.hk/eIPOAllotment  for the full list of allottees.
INTERNATIONAL OFFERING
No. of placees 208
Subscription Level 33.86 times
No. of Offer Shares initially available under the International
Offering
191,167,500
No. of Offer Shares reallocated to the Hong Kong Public
Offering (claw-back)
30,184,500
Final no. of Offer Shares under the International Offering
(after reallocation)
160,983,000
% of Offer Shares under the International Offering to the
Global Offering
80%


--- page 6 ---
6
The Directors confirm that, to the best of their knowledge, information and belief, save for
consent under paragraphs 1C(1) and 1C(2) of Appendix F1 to the Listing Rules and Chapter
2.5 and Chapter 4.15 of the Stock Exchange ’s Guide for New Listing Applicants (the “Placing
Guidelines ”) granted by the Stock Exchange to permit the Company to allocate certain Offer
Shares in the International Offering to existing Shareholder, close associates of existing
Shareholders and connected clients of the overall coordinator(s), any syndicate member(s)
(other than the overall coordinator(s)) or any distributor(s) (other than syndicate member(s))
as a cornerstone investor and a placee, (i) none of the Offer Shares subscribed by the placees
and the public have been financed directly or indirectly by the Company, any of the Directors,
chief executive of the Company, Single Largest Shareholders, substantial shareholders, existing
shareholders of the Company or any of its subsidiaries or their respective close associates; and (ii)
none of the placees and the public who have purchased the Offer Shares are accustomed to taking
instructions from the Company, any of the Directors, chief executive of the Company, Single
Largest Shareholders, substantial shareholders, existing shareholders of the Company or any of its
subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or
other disposition of Shares registered in his/her/its name or otherwise held by him/her/it.


--- page 7 ---
7
The placees in the International Offering include the following:
Cornerstone Investors
Investor
No. of Offer
Shares
allocated
% of Offer
Shares
(assuming
the Over-
allotment
Option is not
exercised)
% of total
issued H
Shares after
the Global
Offering
(assuming
the Over-
allotment
Option is not
exercised)
% of total
issued share
capital after
the Global
Offering
(assuming
the Over-
allotment
Option is not
exercised)
Existing
shareholders
or their close
associates
BlackRock 37,304,500 18.54% 3.54% 3.24% No
UBS AM Singapore 11,191,000 5.56% 1.06% 0.97% No
China Venture Capital
Innovation Investment Fund
Co., Ltd.
7,460,500 3.71% 0.71% 0.65% No
Mirae 5,968,500 2.97% 0.57% 0.52% No
HHLRA 5,968,500 2.97% 0.57% 0.52% No
Deerfield 3,730,000 1.85% 0.35% 0.32% No
RTW Funds 3,730,000 1.85% 0.35% 0.32% No
Arc Avenue 3,730,000 1.85% 0.35% 0.32% No
Huadeng Technology 3,730,000 1.85% 0.35% 0.32% No
Isometry Global 3,730,000 1.85% 0.35% 0.32% No
GF Fund 3,730,000 1.85% 0.35% 0.32% No
ICBCUBS Entities 3,730,000 1.85% 0.35% 0.32% No
China AMC (HK) 3,730,000 1.85% 0.35% 0.32% No
Fullgoal Fund 3,730,000 1.85% 0.35% 0.32% No
Lake Bleu 2,984,000 1.48% 0.28% 0.26% No
Sage Partners 2,984,000 1.48% 0.28% 0.26% No
ICBC Wealth Management 1,492,000 0.74% 0.14% 0.13% No
ORIX Asia AM 1,492,000 0.74% 0.14% 0.13% No
Total 110,415,000 54.87% 10.49% 9.58 %
Note:
1. For further details of the cornerstone investors, please refer to the section headed “Cornerstone Investors ” of the
Prospectus.


--- page 8 ---
8
Allottees with Waivers/Consents Obtained
Investor
No. of Offer
Shares
allocated
% of Offer
Shares
(assuming
the Over-
allotment
Option is not
exercised)
% of total
issued H
Shares after
the Global
Offering
(assuming
the Over-
allotment
Option is not
exercised)
% of total
issued share
capital after
the Global
Offering
(assuming
the Over-
allotment
Option is not
exercised) Relationship
Allottees with waiver from strict compliance with the requirements under Rule 10.04 of the Listing Rules and
consent under paragraph 1C(2) of the Placing Guidelines in relation to allocations to existing Shareholders and
close associates of existing Shareholders (Note 1)
Placees
Martis Fund 3,730,500 1.85% 0.35% 0.32% A placee,
an existing
shareholder
and a close
associate of
an existing
shareholder
Yael Capital Management
Limited
4,477,000 2.22% 0.43% 0.39% A placee and a
close associate
of an existing
shareholder
Mr. Tse Eric S Y 746,500 0.37% 0.07% 0.06% A placee and a
close associate
of an existing
shareholder
China Life Franklin Asset
Management Co., Limited
261,000 0.13% 0.02% 0.02% A placee and a
close associate
of an existing
shareholder
Subtotal 9,215,000 4.58% 0.88% 0.80%


--- page 9 ---
9
Investor
No. of Offer
Shares
allocated
% of Offer
Shares
(assuming
the Over-
allotment
Option is not
exercised)
% of total
issued H
Shares after
the Global
Offering
(assuming
the Over-
allotment
Option is not
exercised)
% of total
issued share
capital after
the Global
Offering
(assuming
the Over-
allotment
Option is not
exercised) Relationship
Allottees with consent under paragraph 1C(1) of the Placing Guidelines and Chapter 4.15 of the Guide for New
Listing Applicants in relation to allocations to connected clients (Note2)
China AMC (HK) 3,730,000 1.85% 0.35% 0.32% Connected
client as a
cornerstone
CITIC Securities Asset
Management Company
Limited ( “CITIC Asset
Management ”)
1,500 0.0007% 0.0001% 0.0001% Connected
client as a
placee
CITIC Securities Asset
Management (HK) Limited
(“CITIC Securities Asset ”)
1,500 0.0007% 0.0001% 0.0001% Connected
client as a
placee
Harvest Global Investments
Limited ( “Harvest ”)
12,000 0.006% 0.001% 0.001% Connected
client as a
placee
DWS Investments Hong
Kong Limited ( “DWS”)
12,000 0.006% 0.001% 0.001% Connected
client as a
placee
HSBC Global Asset
Management (Hong Kong)
Limited ( “HSBC AM ”)
373,000 0.19% 0.04% 0.03% Connected
client as a
placee
CITIC Securities
International Capital
Management Limited
(“CSI”)
2,348,500 1.17% 0.22% 0.20% Connected
client as a
placee
Subtotal 6,478,500 3.22% 0.62% 0.56%


--- page 10 ---
10
Investor
No. of Offer
Shares
allocated
% of Offer
Shares
(assuming
the Over-
allotment
Option is not
exercised)
% of total
issued H
Shares after
the Global
Offering
(assuming
the Over-
allotment
Option is not
exercised)
% of total
issued share
capital after
the Global
Offering
(assuming
the Over-
allotment
Option is not
exercised) Relationship
Notes:
1. See the section headed “Others/Additional Information {  Placing to the existing shareholders and/or their
close associates with a prior waiver under Rule 10.04 of the Listing Rules and consent under paragraph 1C(2)
of the Placing Guidelines ” in this announcement for further details.
2. See “Waivers { Consent in respect of the Proposed Subscription of the Offer Shares by Connected Client ”
of the Prospectus and the section headed “Others/Additional Information {  Placing to connected clients with
a prior consent under paragraph 1C(1) of the Placing Guidelines ” in this announcement for further details.
LOCK-UP UNDERTAKINGS
Key Persons (Note 1) (as Defined under Rule 18C.14 of the Listing Rules)
Name Capacity
Number of
Shares held in
the Company
subject to lock-
up
undertakings
upon listing
% of total
issued Shares
after the
Global Offering
upon Listing
(assuming the
Over-allotment
Option is not
exercised)
Last day subject
to the lock-up
undertakings (Note 2)
Dr. Lai Co-founder, chairman
of the Board, executive
Director and chief
executive officer
{ { May 12, 2028
Scientia HK Dr. Lai ’s close associate 121,334,260 10.53% May 12, 2028
Delos Holding Dr. Lai ’s close associate 16,000,000 1.39% May 12, 2028
Dechi Holding Dr. Lai ’s close associate 10,232,590 0.89% May 12, 2028
Dr. Chen Co-founder, executive
Director and chief
research and development
officer
66,913,490 5.81% May 12, 2028
Dr. Wang Co-founder, executive
Director and chief
operating officer
34,911,380 3.03% May 12, 2028


--- page 11 ---
11
Name Capacity
Number of
Shares held in
the Company
subject to lock-
up
undertakings
upon listing
% of total
issued Shares
after the
Global Offering
upon Listing
(assuming the
Over-allotment
Option is not
exercised)
Last day subject
to the lock-up
undertakings (Note 2)
Nanjing Chengtai
Yuxin
Dr. Wang ’s close
associate
25,857,170 2.24% May 12, 2028
Hangzhou Shengtai Dr. Wang ’s close
associate
16,524,730 1.43% May 12, 2028
Subtotal 291,773,620 25.32%
Notes:
1. Dr. Lai, Dr. Chen and Dr. Wang are our Co-founders, executive Directors and senior management, each
being our key persons responsible for our technical operations and/or the research and development of our
Specialist Technology Products, who are subject to lock-up requirements pursuant to Rule 18C.14 of the
Listing Rules. In addition, our key persons for the purpose of Rule 18C.14 of the Listing Rules also include
(i) Dr. Alan Fu, Dr. Wei Xu and Mr. Mark Robert Herbert, each being a senior management member of the
Company, and (ii) Dr. Andong Liu, our vice president and head of technology and one of our key personnel
responsible for our Company ’s technical operations and/or the research and development of our Specialist
Technology Products (collectively, the “Other Key Persons ”). As of the date of the Prospectus, the Other
Key Persons held certain Equity Incentives under our Employee Incentive Schemes, for further details of the
Employee Incentives, please refer to section headed “Appendix V {  Statutory and General Information {
Further Information about our Directors, Senior Management and Substantial Shareholders {  5. Employee
Incentive Schemes. ” in the Prospectus.
2. The lock-up period commences on the date by reference to which disclosure of its shareholding is made in
the Prospectus and ends on the date which is 24 months from the Listing Date, i.e. May 12, 2028. In the
event that upon the notification by the Stock Exchange that the Company will no longer be regarded as a Pre-
Commercial Company after the Listing, the lock-up period will expire on the later of: (i) the date on which
such lock-up periods would have ended if the Company had applied for listing as a Commercial Company;
and (ii) the date falling on the 30th day after the announcement on the removal of designation as a Pre-
Commercial Company as required under Rule 18C.24 of the Listing Rules.


--- page 12 ---
12
Pathfinder SIIs
Name Note 1 Capacity
Number
of Shares
held in the
Company
subject to
lock-up
undertakings
upon
Listing
% of total
issued
Shares after
the Global
Offering
upon Listing
(assuming
the Over-
allotment
Option is not
exercised)
Last day subject to
the lock-up
undertakings (Note 1)
CICC Pathfinder SIIs 108,800,000 9.44% May 12, 2027
HSG Pathfinder SIIs 65,558,660 5.69% May 12, 2027
Beijing PICC Health
and Pension Industry
Investment Fund
(Limited Partnership)
(਄ੰቮϼପ
ږ( Υ
ྫ)) ( “PICC Health
& Pension Fund ”)
Pathfinder SIIs 50,324,060 4.37% May 12, 2027
5Y Capital Pathfinder SIIs 45,463,970 3.94% May 12, 2027
Jiangsu Jiequan
Chengda Equity
Investment Centre
(Limited Partnership)
(ᛆҳ
༟ʕː(Υྫ ))
Pathfinder SIIs 35,025,550 3.04% May 12, 2027
Note:
1. In accordance with Rule 18C.14 of the Listing Rules, the required lock-up period commences on the date
by reference to which disclosure of its shareholding is made in the Prospectus and ends on the date which
is 12 months from the Listing Date, i.e. May 12, 2027. In the event that upon the notification by the Stock
Exchange that the Company will no longer be regarded as a Pre-Commercial Company after the Listing, the
lock-up period will expire on the later of: (i) the date on which such lock-up periods would have ended if the
Company had applied for listing as a Commercial Company; and (ii) the date falling on the 30th day after the
announcement on the removal of designation as a Pre-Commercial Company as required under Rule 18C.24
of the Listing Rules.


--- page 13 ---
13
Single Largest Shareholders
Name Note 1 Capacity
Number
of Shares
held in the
Company
subject to
lock-up
undertakings
upon Listing
% of total
issued
Shares after
the Global
Offering
upon Listing
(assuming
the Over-
allotment
Option is not
exercised)
Last day subject
to the lock-up
undertakings (Note 1)
Dr. Wang Beneficial Interest 34,911,380 3.03% May 12, 2028
Dr. Chen Beneficial Interest 66,913,490 5.81% May 12, 2028
Dr. Lai/Scientia
 HK (Note 2)
Beneficial Interest 121,334,260 10.53% May 12, 2028
Delos(Note 3) Beneficial Interest 16,000,000 1.39% May 12, 2028
Nanjing Chengtai
Yuxin
Beneficial Interest 25,857,170 2.24% May 12, 2028
Hangzhou Shengtai Beneficial Interest 16,524,730 1.43% May 12, 2028
Dechi Holding (Note 4) Beneficial Interest 10,232,590 0.89% May 12, 2028
Notes:
1. The lock-up period commences on the date by reference to which disclosure of its shareholding is made in
the Prospectus and ends on the date which is 24 months from the Listing Date, i.e. May 12, 2028. In the
event that upon the notification by the Stock Exchange that the Company will no longer be regarded as a Pre-
Commercial Company after the Listing, the lock-up period will expire on the later of: (i) the date on which
such lock-up periods would have ended if the Company had applied for listing as a Commercial Company;
and (ii) the date falling on the 30th day after the announcement on the removal of designation as a Pre-
Commercial Company as required under Rule 18C.24 of the Listing Rules.
2. Scientia HK Limited, a private company limited by shares incorporated on February 17, 2023, which is
wholly owned by Dr. Lai.
3. As of the date of this announcement, Delos Holding was controlled by Dr. Lai as to approximately 38.57%
and the remaining 61.43% equity interests were held by the relevant grantees under the 2023 Equity Incentive
Plan, none of whom holds 30% or more of the equity interests therein.
4. As of the date of this announcement, Dechi Holding was owned as to (i) 3.91% by Dr. Lai; (ii) 44.82% by Dr.
Alan Fu; (iii) 34.04% by Mr. Mark Robert Herbert; and (iv) 17.23% by three consultants of our Company.
Dr. Lai controlled Dechi Holding through the only one management share he held and he is also responsible
for the day-to-day decision making of Dechi Holding.


--- page 14 ---
14
Existing Shareholders
Name
Number of
Shares held in
the Company
subject to
lock-up
undertakings
upon Listing
Number of H
Shares held in
the Company
subject to
lock-up
undertakings
upon Listing
% of total
issued
Shares after
the Global
Offering
upon Listing
(assuming
the Over-
allotment
Option is not
exercised)
% of total
issued H
shares after
the Global
Offering
upon Listing
(assuming
the Over-
allotment
Option is not
exercised)
Last day
subject to
the lock-up
undertakings
Dr. Wang 34,911,380 24,437,966 3.03% 2.32% May 12, 2028
Dr. Chen 66,913,490 46,839,443 5.81% 4.45% May 12, 2028
Dr. Lai/Scientia HK (Note 1) 121,334,260 84,933,982 10.53% 8.07% May 12, 2028
Delos (Note 2) 16,000,000 16,000,000 1.39% 1.52% May 12, 2028
Nanjing Chengtai Yuxin 25,857,170 25,857,170 2.24% 2.46% May 12, 2028
Hangzhou Shengtai 16,524,730 16,524,730 1.43% 1.57% May 12, 2028
Dechi Holding (Note 3) 10,232,590 10,232,590 0.89% 0.97% May 12, 2028
Beijing Yuhetai 985,000 985,000 0.09% 0.09% May 12, 2027
CICC Kangrui 72,533,330 50,773,331 6.29% 4.82% May 12, 2027
PICC Health & Pension
Fund
50,324,060 50,324,060 4.37% 4.78% May 12, 2027
Evolution Holding 31,916,730 31,916,730 2.77% 3.03% May 12, 2027
HSG Seed I 43,420,100 43,420,100 3.77% 4.12% May 12, 2027
LS Metis 43,225,210 43,225,210 3.75% 4.11% May 12, 2027
Martis Fund 42,616,430 42,616,430 3.70% 4.05% May 12, 2027
XtalPi 32,146,460 32,146,460 2.79% 3.05% May 12, 2027
CICC Healthcare 36,266,670 25,386,669 3.15% 2.41% May 12, 2027
Jiequan Chengda 35,025,550 35,025,550 3.04% 3.33% May 12, 2027
Matrice Capital 30,620,100 30,620,100 2.66% 2.91% May 12, 2027
Duckling Fund 29,771,710 29,771,710 2.58% 2.83% May 12, 2027
FreeS 27,235,920 27,235,920 2.36% 2.59% May 12, 2027


--- page 15 ---
15
Name
Number of
Shares held in
the Company
subject to
lock-up
undertakings
upon Listing
Number of H
Shares held in
the Company
subject to
lock-up
undertakings
upon Listing
% of total
issued
Shares after
the Global
Offering
upon Listing
(assuming
the Over-
allotment
Option is not
exercised)
% of total
issued H
shares after
the Global
Offering
upon Listing
(assuming
the Over-
allotment
Option is not
exercised)
Last day
subject to
the lock-up
undertakings
HSG Venture VIII 22,138,560 22,138,560 1.92% 2.10% May 12, 2027
Guangzhou CMB 16,251,850 16,251,850 1.41% 1.54% May 12, 2027
Vibrant Evolution 13,547,240 13,547,240 1.18% 1.29% May 12, 2027
IMO Global 6,094,450 6,094,450 0.53% 0.58% May 12, 2027
Chia Tai Pharmaceutical
Group Investment Co.,
Limited
8,051,850 8,051,850 0.70% 0.76% May 12, 2027
Kunshan Fengrui 7,734,860 7,734,860 0.67% 0.73% May 12, 2027
YUAN BEN CHEN XING 7,236,680 7,236,680 0.63% 0.69% May 12, 2027
Monolith 6,773,620 6,773,620 0.59% 0.64% May 12, 2027
Chengdu Fengrui 5,366,960 5,366,960 0.47% 0.51% May 12, 2027
Tianjin Taixi 4,064,170 4,064,170 0.35% 0.39% May 12, 2027
Yael Capital 2,616,850 2,616,850 0.23% 0.25% May 12, 2027
Taiping GBA 2,417,780 2,417,780 0.21% 0.23% May 12, 2027
Yael Evergreen 2,415,560 2,415,560 0.21% 0.23% May 12, 2027
Nanjing CMB 1,260,920 1,260,920 0.11% 0.12% May 12, 2027
Shanghai Ziyuan 875,640 875,640 0.08% 0.08% May 12, 2027
Alaya Capital Partners
Limited
25,155,100 25,155,100 2.18% 2.39% May 12, 2027
Beijing Medical and Health 25,734,780 25,734,780 2.23% 2.44% May 12, 2027
Beijing Daxing 19,301,080 19,301,080 1.67% 1.83% May 12, 2027
AHI Investment 6,386,010 6,386,010 0.55% 0.61% May 12, 2027
Notes:
1. Scientia HK Limited, a private company limited by shares incorporated on February 17, 2023, which is
wholly owned by Dr. Lai.
2. As of the date of this announcement, Delos Holding was controlled by Dr. Lai as to approximately 38.57%
and the remaining 61.43% equity interests were held by the relevant grantees under the 2023 Equity Incentive
Plan, none of whom holds 30% or more of the equity interests therein.
3. As of the date of this announcement, Dechi Holding was owned as to (i) 3.91% by Dr. Lai; (ii) 44.82% by Dr.
Alan Fu; (iii) 34.04% by Mr. Mark Robert Herbert; and (iv) 17.23% by three consultants of our Company.
Dr. Lai controlled Dechi Holding through the only one management share he held and he is also responsible
for the day-to-day decision making of Dechi Holding.


--- page 16 ---
16
Cornerstone Investors
Name
Number of
Shares held in
the Company
subject to lock-up
undertakings
upon Listing
% of total issued
Shares after the
Global Offering
upon Listing
(assuming the
Over-allotment
Option is not
exercised)
Last day subject to
the lock-up
undertakings (Note 1)
BlackRock 37,304,500 3.24% November 12, 2026
UBS AM Singapore 11,191,000 0.97% November 12, 2026
China Venture Capital
Innovation Investment Fund
Co., Ltd.
7,460,500 0.65% November 12, 2026
Mirae 5,968,500 0.52% November 12, 2026
HHLRA 5,968,500 0.52% November 12, 2026
Deerfield 3,730,000 0.32% November 12, 2026
RTW Funds 3,730,000 0.32% November 12, 2026
Arc Avenue 3,730,000 0.32% November 12, 2026
Huadeng Technology 3,730,000 0.32% November 12, 2026
Isometry Global 3,730,000 0.32% November 12, 2026
GF Fund 3,730,000 0.32% November 12, 2026
ICBCUBS Entities 3,730,000 0.32% November 12, 2026
China AMC (HK) 3,730,000 0.32% November 12, 2026
Fullgoal Fund 3,730,000 0.32% November 12, 2026
Lake Bleu 2,984,000 0.26% November 12, 2026
Sage Partners 2,984,000 0.26% November 12, 2026
ICBC Wealth Management 1,492,000 0.13% November 12, 2026
ORIX Asia AM 1,492,000 0.13% November 12, 2026
Note:
1. In accordance with the relevant cornerstone investment agreements, the required lock-up periods will end on
November 12, 2026. The Cornerstone Investors will cease to be prohibited from disposing of or transferring
the H Shares subscribed for pursuant to the relevant cornerstone investment agreements after the indicated
date.


--- page 17 ---
17
PLACEE CONCENTRATION ANALYSIS
Placees
Number of H
Shares allotted
Allotment as %
of International
Offering
(assuming the
Over-allotment
Option is not
exercised)
Allotment as %
of International
Offering
(assuming the
Over-allotment
Option is fully
exercised)
Allotment as
% of total
Offer Shares
(assuming the
Over-allotment
Option is not
exercised)
Allotment as
% of total
Offer Shares
(assuming the
Over-allotment
Option is fully
exercised)
Number of
Shares held
upon Listing
% of total
issued share
capital upon
Listing
(assuming the
Over-allotment
Option is not
exercised)
% of total
issued share
capital upon
Listing
(assuming the
Over-allotment
Option is fully
exercised)
Top 1 37,304,500 23.17% 19.51% 18.54% 16.12% 37,304,500 3.24% 3.15%
Top 5 67,893,000 42.17% 35.52% 33.74% 29.34% 67,893,000 5.89% 5.74%
Top 10 89,157,000 55.38% 46.64% 44.31% 38.53% 166,577,550 14.45% 14.08%
Top 25 136,903,500 85.04% 71.61% 68.03% 59.16% 214,324,050 18.60% 18.12%
Note
* Ranking of placees is based on the number of H Shares allotted to the placees.
H SHAREHOLDERS CONCENTRATION ANALYSIS
H Shareholders
Number of
H Shares
allotted
Allotment
as % of
International
Offering
(assuming
the Over-
allotment
Option is not
exercised)
Allotment
as % of
International
Offering
(assuming
the Over-
allotment
Option
is fully
exercised)
Allotment
as % of
total Offer
Shares
(assuming
the Over-
allotment
Option is not
exercised)
Allotment
as % of
total Offer
Shares
(assuming
the Over-
allotment
Option
is fully
exercised)
Number
of H Shares
held upon
Listing
% of total
issued
H share
capital upon
Listing
(assuming
the Over-
allotment
Option is not
exercised)
% of total
issued
H share
capital upon
Listing
(assuming
the Over-
allotment
Option
is fully
exercised)
% of total
issued share
capital upon
Listing
(assuming
the Over-
allotment
Option is not
exercised)
% of total
issued share
capital upon
Listing
(assuming
the Over-
allotment
Option
is fully
exercised)
Top 1 0 0.00% 0.00% 0.00% 0.00% 224,825,881 21.35% 20.76% 19.51% 19.01%
Top 5 3,730,500 2.32% 1.95% 1.85% 1.61% 492,987,241 46.82% 45.52% 42.77% 41.68%
Top 10 41,035,000 25.49% 21.47% 20.39% 17.73% 705,230,161 66.98% 65.11% 61.19% 59.63%
Top 25 77,108,000 47.90% 40.34% 38.32% 33.32% 921,338,161 87.50% 85.06% 79.94% 77.90%
Note
* Ranking of H Shareholders is based on the number of H Shares held by the H Shareholders upon Listing.


--- page 18 ---
18
SHAREHOLDER CONCENTRATION ANALYSIS
Shareholders
Number of
H Shares
allotted
Allotment
as %of
International
Offering
(assuming the
Over-allotment
Option is not
exercised)
Allotment
as % of
International
Offering
(assuming the
Over-allotment
Option is fully
exercised)
Allotment
as % of total
Offer Shares
(assuming the
Over-allotment
Option is not
exercised)
Allotment as
% of total
Offer Shares
(assuming the
Over-allotment
Option is fully
exercised)
Number of H
Shares held
upon Listing
Number of
Shares held
upon Listing
% of total
issued share
capital upon
Listing
(assuming the
Over-allotment
Option is not
exercised)
% of total
issued share
capital upon
Listing
(assuming the
Over-allotment
Option is fully
exercised)
Top 1 0 0.00% 0.00% 0.00% 0.00% 224,825,881 291,773,620 25.32% 24.67%
Top 5 3,730,500 2.32% 1.95% 1.85% 1.61% 492,987,241 592,574,980 51.42% 50.10%
Top 10 41,035,000 25.49% 21.47% 20.39% 17.73% 705,230,161 804,817,900 69.83% 68.05%
Top 25 77,108,000 47.90% 40.34% 38.32% 33.32% 921,338,161 1,020,925,900 88.58% 86.32%
Note
* Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholder upon Listing.


--- page 19 ---
19
BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING
Subject to the satisfaction of the conditions set out in the Prospectus, valid applications made by
the public will be conditionally allocated on the basis set out below:
METIS TECHBIO CO., LTD. FINAL
BASIS OF ALLOTMENT FOR PRESS ANNOUNCEMENT
NO. OF SHARES
APPLIED FOR
NO. OF VALID
APPLICATIONS BASIS OF ALLOTMENT/BALLOT
APPROXIMATE
PERCENTAGE
ALLOTTED OF THE
TOTAL NO. OF
SHARES APPLIED FOR
POOL A
500 93,334 132 out of 93,334 to receive 500 Shares 0.14%
1,000 18,254 52 out of 18,254 to receive 500 Shares 0.14%
1,500 10,141 43 out of 10,141 to receive 500 Shares 0.14%
2,000 19,104 108 out of 19,104 to receive 500 Shares 0.14%
2,500 9,301 66 out of 9,301 to receive 500 Shares 0.14%
3,000 7,928 67 out of 7,928 to receive 500 Shares 0.14%
3,500 3,341 33 out of 3,341 to receive 500 Shares 0.14%
4,000 4,849 55 out of 4,849 to receive 500 Shares 0.14%
4,500 7,406 94 out of 7,406 to receive 500 Shares 0.14%
5,000 11,684 165 out of 11,684 to receive 500 Shares 0.14%
6,000 4,628 79 out of 4,628 to receive 500 Shares 0.14%
7,000 4,081 81 out of 4,081 to receive 500 Shares 0.14%
8,000 8,387 190 out of 8,387 to receive 500 Shares 0.14%
9,000 8,546 218 out of 8,546 to receive 500 Shares 0.14%
10,000 14,292 405 out of 14,292 to receive 500 Shares 0.14%
15,000 10,263 436 out of 10,263 to receive 500 Shares 0.14%
20,000 8,514 482 out of 8,514 to receive 500 Shares 0.14%
25,000 6,592 466 out of 6,592 to receive 500 Shares 0.14%
30,000 5,475 465 out of 5,475 to receive 500 Shares 0.14%
35,000 3,934 390 out of 3,934 to receive 500 Shares 0.14%
40,000 3,937 446 out of 3,937 to receive 500 Shares 0.14%
45,000 3,223 411 out of 3,223 to receive 500 Shares 0.14%
50,000 7,194 1,018 out of 7,194 to receive 500 Shares 0.14%
60,000 4,694 797 out of 4,694 to receive 500 Shares 0.14%
70,000 3,578 709 out of 3,578 to receive 500 Shares 0.14%
80,000 4,111 931 out of 4,111 to receive 500 Shares 0.14%
90,000 3,663 933 out of 3,663 to receive 500 Shares 0.14%
100,000 18,906 5,351 out of 18,906 to receive 500 Shares 0.14%
200,000 12,147 6,876 out of 12,147 to receive 500 Shares 0.14%
300,000 8,069 6,852 out of 8,069 to receive 500 Shares 0.14%
400,000 10,507 500 Shares plus 1,388 out of 10,507 to receive
additional 500 Shares
0.14%
340,083 Total number of Pool A successful applicants: 38,858


--- page 20 ---
20
METIS TECHBIO CO., LTD. FINAL
BASIS OF ALLOTMENT FOR PRESS ANNOUNCEMENT
NO. OF SHARES
APPLIED FOR
NO. OF VALID
APPLICATIONS BASIS OF ALLOTMENT/BALLOT
APPROXIMATE
PERCENTAGE
ALLOTTED OF THE
TOTAL NO. OF
SHARES APPLIED FOR
POOL B
500,000 22,231 8,087 out of 22,231 to receive 500 Shares 0.04%
1,000,000 8,076 5,876 out of 8,076 to receive 500 Shares 0.04%
1,500,000 3,977 500 Shares plus 363 out of 3,977 to receive additional
500 Shares
0.04%
2,000,000 2,363 500 Shares plus 1,075 out of 2,363 to receive
additional 500 Shares
0.04%
2,500,000 1,455 500 Shares plus 1,192 out of 1,455 to receive
additional 500 Shares
0.04%
3,000,000 989 1,000 Shares plus 181 out of 989 to receive additional
500 Shares
0.04%
3,500,000 650 1,000 Shares plus 355 out of 650 to receive additional
500 Shares
0.04%
4,000,000 949 1,000 Shares plus 864 out of 949 to receive additional
500 Shares
0.04%
5,030,500 2,536 1,500 Shares plus 1,674 out of 2,536 to receive
additional 500 Shares
0.04%
43,226 Total number of Pool B successful applicants: 26,882


--- page 21 ---
21
As of the date of this announcement, the relevant subscription monies previously deposited in the
designated nominee accounts have been remitted back to the accounts of all HKSCC participants.
Investors should contact their relevant brokers for any inquiries.
COMPLIANCE WITH LISTING RULES AND GUIDANCE
The Directors confirm that, except for the Listing Rules that have been waived and/or in respect of
which consent has been obtained, the Company has complied with the Listing Rules and guidance
materials in relation to the placing, allotment and listing of the H Shares.
The Directors confirm that, to the best of their knowledge, the consideration paid by the placees
or the public (as the case may be) directly or indirectly for each Offer Share subscribed for or
purchased by them was the same as the Offer Price in addition to any brokerage, AFRC transaction
levy, SFC transaction levy and Stock Exchange trading fee payable.
The Directors and the Overall Coordinators confirm that at least 50% of the total number of
the Offer Shares have been allocated to and taken up by independent price setting investors in
compliance with Rule 18C.08 of the Listing Rules.
The Directors further confirm that at least 25% of the issued share capital of the Company will be
held by sophisticated independent investors at the time of Listing in compliance with Chapter 2.5
of the Guide for New Listing Applicants.
OTHERS/ADDITIONAL INFORMATION
Reallocation
As the Hong Kong Public Offering has been oversubscribed 50 times or more, the reallocation
as described in the section headed “Structure of the Global Offering {  The Hong Kong Public
Offering { Reallocation and Clawback ” of the Prospectus has been applied. As a result of
the above, the final number of Offer Shares under the Hong Kong Public Offering is adjusted
to 40,246,000 Shares, representing approximately 20.00% of the total number of Offer Shares
available under the Global Offering (assuming the Over-allotment Option is not exercised), and the
final number of Offer Shares under the International Offering is adjusted to 160,983,000 Shares,
representing approximately 80.00% of the total number of Offer Shares under the Global Offering
(assuming the Over-allotment Option is not exercised).


--- page 22 ---
22
Placing to the existing shareholders and/or their close associates with a prior waiver under
Rule 10.04 of the Listing Rules and consent under paragraph 1C(2) of the Placing Guidelines
The Company has applied for a waiver under Rule 10.04 of the Listing Rules and a consent under
paragraph 1C(2) of Appendix F1 to the Listing Rules, to permit the existing shareholders and/or its
close associates to participate as placees in the Global Offering to subscribe for the Offer Shares to
be issued by the Company under the International Offering (together, the “Existing Shareholder
Participants ”). The Stock Exchange has agreed to grant the requested waiver and consent subject
to the conditions that:
(a) the allocation to the Existing Shareholder Participants will not affect the Company ’s ability
to satisfy its public float requirement under Rule 8.08(1) (as amended and replaced by Rule
19A.13A) and 18C.08 of the Listing Rules;
(b) the Company and the Joint Sponsors confirm that no preferential treatment has been, nor will
be directly or indirectly, given to the Existing Shareholder Participants as placees by virtue of
their relationship with the Company in any allocation in the Global Offering, other than the
preferential treatment of assured entitlement under the cornerstone investment at the Offer
Price and the terms are substantially the same as other cornerstone investors; and
(c) details of the subscription of the Offer Shares by the Existing Shareholder Participants as
placees under the Global Offering are disclosed in this allotment results announcement of the
Company.


--- page 23 ---
23
For details of the allocations of Offer Shares to such Existing Shareholder Participants, please
refer to the section headed “Allotment Results Details {  International Offering {  Allottees with
Waivers/Consents Obtained ” in this announcement.
Placing to connected clients with a prior consent under paragraph 1C(1) of the Placing
Guidelines
Under the International Offering, certain Offer Shares were placed to connected clients of their
connected distributors pursuant to the Placing Guidelines.
The Company has applied to the Stock Exchange for, and the Stock Exchange has granted, a
consent under paragraph 1C(1) of the Placing Guidelines to permit the Company to allocate such
Offer Shares in the International Offering to the connected clients. The allocation of Offer Shares
to such connected clients is in compliance with all the conditions under the consent granted by the
Stock Exchange. Details of the placement to connected clients are set out below:
No. Connected Distributor Connected Client
Relationship with the Connected
Distributor
Identities of
the ultimate
beneficial
owners of the
Offer Shares
Whether the
Connected
Client is a
collective
investment
scheme which is
not authorised
by the SFC or is
expected to hold
the Offer Shares
on behalf of
such scheme
Number of
Offer Shares
allocated to
the connected
client
Approximate
percentage of
total number
of Offer
Shares under
the Global
Offering
(assuming no
exercise of the
Over-allotment
Option)
Approximate
percentage
of total
issued share
capital after
the Global
Offering
(assuming no
exercise of the
Over-allotment
Option)
Part A {  Connected Clients holding the beneficial interest of the Offer Shares on a discretionary basis on behalf of independent third parties
1. CLSA Limited
(“CLSA”)
CITIC Securities Asset
Management Company
Limited ( “CITIC Asset
Management ”)
CLSA and CITIC Asset
Management, are members of the
same group of companies.
Please refer to
Note 1
Yes 1,500 0.0007% 0.0001%
2. CLSA CITIC Securities Asset
Management (HK) Limited
(“CITIC Securities
Asset ”)
CITIC Securities Asset is a member
of the same group of companies as
CLSA.
Please refer to
Note 2
No 1,500 0.0007% 0.0001%


--- page 24 ---
24
No. Connected Distributor Connected Client
Relationship with the Connected
Distributor
Identities of
the ultimate
beneficial
owners of the
Offer Shares
Whether the
Connected
Client is a
collective
investment
scheme which is
not authorised
by the SFC or is
expected to hold
the Offer Shares
on behalf of
such scheme
Number of
Offer Shares
allocated to
the connected
client
Approximate
percentage of
total number
of Offer
Shares under
the Global
Offering
(assuming no
exercise of the
Over-allotment
Option)
Approximate
percentage
of total
issued share
capital after
the Global
Offering
(assuming no
exercise of the
Over-allotment
Option)
Part A {  Connected Clients holding the beneficial interest of the Offer Shares on a discretionary basis on behalf of independent third parties
3. Deutsche Bank AG,
Hong Kong Branch
(“DBHK”)
Harvest Global Investments
Limited ( “Harvest ”)
Harvest is a wholly-owned
subsidiary of Harvest Financial
Group Limited, which in turn is
wholly owned by Harvest Fund
Management Co., Ltd. Harvest
Fund Management Co., Ltd. is
30% owned by DWS Investments
Singapore Limited. DWS
Investments Singapore Limited
is a wholly-owned subsidiary
of DWS Group GmbH & Co.
KGaA. DWS Group GmbH &
Co. KGaA is partially owned by
DB Beteiligungs-Holdings GmbH
(79.49%), Nippon Life Insurance
(5%) and outside shareholders
(15.51 %) as at Dec 31, 2025. DB
Beteiligungs-Holdings GmbH is
wholly owned by Deutsche Bank
AG.
Please refer to
Note 3
No 12,000 0.006% 0.001%
4. DBHK DWS Investments Hong
Kong Limited ( “DWS”)
DWS is a wholly-owned subsidiary
of DWS Group GmbH & Co.
KGaA. DWS Group GmbH &
Co. KGaA is partially owned by
DB Beteiligungs-Holdings GmbH
(79.49%), Nippon Life Insurance
(5%) and outside shareholders
(15.51%) as at December 31, 2025.
DB Beteiligungs-Holdings GmbH
is wholly owned by Deutsche Bank
AG.
Please refer to
Note 4
No 12,000 0.006% 0.001%


--- page 25 ---
25
No. Connected Distributor Connected Client
Relationship with the Connected
Distributor
Identities of
the ultimate
beneficial
owners of the
Offer Shares
Whether the
Connected
Client is a
collective
investment
scheme which is
not authorised
by the SFC or is
expected to hold
the Offer Shares
on behalf of
such scheme
Number of
Offer Shares
allocated to
the connected
client
Approximate
percentage of
total number
of Offer
Shares under
the Global
Offering
(assuming no
exercise of the
Over-allotment
Option)
Approximate
percentage
of total
issued share
capital after
the Global
Offering
(assuming no
exercise of the
Over-allotment
Option)
Part A {  Connected Clients holding the beneficial interest of the Offer Shares on a discretionary basis on behalf of independent third parties
5. The Hongkong And
Shanghai Banking
Corporation Limited
(“HSBC”)
HSBC Global Asset
Management (Hong Kong)
Limited ( “HSBC AM ”)
HSBC AM is a fellow subsidiary of
HSBC.
Please refer to
Note 5
No 373,000 0.19% 0.03%
Notes:
1. CITIC Asset Management will hold the Offer Shares in its capacity as the discretionary fund manager managing
the funds on behalf of their investors, each of which is an independent third party.
The funds are as follows: (i) CITIC SECURITIES COMPANY LIMITED-XINHANG ZHIYUAN NO.3(൛
Ⴣ 3 ྌ ), and (ii) CITIC Securities AM-Guibinfengyuan No.118 QDII(൛Վ༟
၍൮Ⴗᔮʩ 118 ໮  QDII ྌ ).
None of the CITIC Asset Management Ultimate Clients holds more than 30% ultimate beneficial interest in the
aforementioned funds, and all of them with discretionary management.
2. CITIC Securities Asset will hold the Offer Shares in its capacity as the discretionary fund manager managing
the funds on behalf of their investors, each of which is an independent third party.
The funds is as follows: CITIC Securities Asset Management (HK) Limited – CLSA CT Limited Sub Account
26. Invested 100% by Roofer Securities Limited, of which UBO holding 30% or more interest is natural person
Karen Liu.


--- page 26 ---
26
3. Harvest will hold the Offer Shares in its capacity as the discretionary fund manager managing the funds on
behalf of their investors, each of which is an independent third party.
The funds are as follows: (i) HARVEST ESG CHINA A RESEARCH SELECT FUND, (ii) ASIA FRONTIER
EQUITY FUND, (iii) Harvest BOCHK Diverse Income Fund, (iv) Harvest Total Return Fund, and (v) HGI IPO
MANDATE NO.1.
No ultimate beneficial owner holds 30% or more interest in the funds.
4. DWS will hold the Offer Shares in its capacity as the discretionary fund manager managing the funds on behalf
of their investors, each of which is an independent third party.
The fund is as follows: DWS Invest Chinese Equities.
No ultimate beneficial owner holds 30% or more interest in the funds.
5. HSBC AM will hold the Offer Shares in its capacity as the discretionary fund manager managing the funds on
behalf of their investors, each of which is an independent third party.
The funds are as follows: (i) HSBC Global Investment Funds Asia Ex Japan Equity Smaller Companies, (ii)
HSBC Global Investment Funds Chinese Equity, (iii) HSBC Global Investment Funds Hong Kong Equity, (iv)
HSBC China Growth Fund, (v) HSBC China Momentum Fund, (vi) HSBC Collective Investment Trust – HSBC
China Multi-Asset Income Fund, (vii) HSBC China Mother Fund, (viii) HSBC Pooled Investment Fund-HSBC
Pooled Chinese Equity Fund, (ix) HSBC Pooled Investment Fund – HK HSBC Pooled Hong Kong Equity Fund,
(x) HSBC Global RAIF Discretionary Asia Equity Next Generation Leaders Portfolio, (xi) HSBC Global RAIF –
Discretionary Asia Equity Portfolio, and (xii) HSHK Asian Small Caps.
No ultimate beneficial owner holds 30% or more interest in the funds.
No.
Connected
Distributor
Connected
Client
Relationship
with the
Connected
Distributor
Identities of the ultimate
beneficial owners of the Offer
Shares or, where applicable,
details of the structured products
under which the subscription by
the Connected Client was made
(e.g. OTC total return swaps)
Whether the
Connected Client
is a collective
investment scheme
which is not
authorised by the
SFC or is expected
to hold the Offer
Shares on behalf of
such scheme
Number of
Offer Shares
allocated
to the
connected
client
Approximate
percentage of total
number of Offer
Shares under the
Global Offering
(assuming no
exercise of the
Over-allotment
Option)
Approximate
percentage of
total issued share
capital after the
Global Offering
(assuming no
exercise of the
Over-allotment
Option)
Part B {  Connected Client holding the beneficial interest of the Offer Shares on a non-discretionary basis on behalf of independent third parties
1. CLSA CITIC Securities
International Capital
Management Limited
(“CSI”)
CSI is a member of
the same group of
companies as CLSA.
Please refer to Note 1 No 2,348,500 1.17% 0.20%
Note:
1. CSI will hold the Offer Shares as a placee under the International Offering on behalf of its ultimate clients
(the “CSI Ultimate Clients ”), on a non-discretionary basis, pursuant to which: (i) CSI will act as the single
counterparty of the CSI Back-to-back TRS (the “CSI Back-to-back TRS ”) to be entered into by it in connection
with a total return swap order (the “CSI Client TRS ”) placed and fully funded by the CSI Ultimate Clients, by
which CSI will pass the full economic exposure of the Offer Shares placed to CSI to the CSI Ultimate Clients;
(ii) as confirmed by CSI and CLSA, CSI will hold the legal title and beneficial interest in the Offer Shares,
but will contractually agree to pass on the full economic exposure and return of the Offer Shares to the CSI
Ultimate Clients, on a non-discretionary basis. The CSI Ultimate Clients may exercise their early termination
rights to terminate the CSI Client TRS at any time from the trade date of the CSI Client TRS which should be
on or after the date on which the Offer Shares are listed on the Stock Exchange; (iii) upon the final maturity
or termination of the CSI Client TRS by the CSI Ultimate Clients, CSI will dispose of the Offer Shares on the
secondary market and the CSI Ultimate Clients will receive a final termination amount of the CSI Back-to-
back TRS which will have taken into account all the economic returns or economic loss in relation to the Offer
Shares and the fixed amount of transaction fees of the CSI Back-to-back TRS and the CSI Client TRS. Due to
its internal policy, CSI will not exercise the voting right of the Offer Shares during the terms of the CSI Back-
to-back TRS; and (iv) CSI is not a collective investment scheme which is not authorized by the SFC, nor is
expected to hold the Offer Shares on behalf of such scheme.


--- page 27 ---
27
The details of the CSI Ultimate Clients are as follows:
Name (CSI Ultimate Client) Asset Manager
UBO of Asset
Manager
UBO of CSI
Ultimate Client
Panjing Wenheng Private Securities Investment
Fund (ږ)
Shanghai Panjing Investment Management
Center (Limited Partnership) ( ɪऎᆵԯҳ༟၍
ଣʕː(Υྫ ))
Zhuang Tao ( ୿ᏹ) None
Panjing Wenheng Phase 2 Private Securities
Investment Fund ( ᆵԯၲ㛬 2 ಂӷ෍ᗇՎҳ༟
ږ)
Shanghai Panjing Investment Management
Center (Limited Partnership) ( ɪऎᆵԯҳ༟၍
ଣʕː(Υྫ ))
Zhuang Tao ( ୿ᏹ) None
Lingding No.3 Private Securities Investment
Fund (ږ)
Ningbo Meishan Bonded Port Area Lingding
Investment Management Co., Ltd. (ૠʆ
ʮ̡ )
Chen Youfang
(௓Ϟ˙),
Deng Chunyan
(ዲ)
Xiong Nawei
(ဤॶฆ)
Yuanle Qiangye Private Securities Investment
Fund (ږ)
Xizang Yuanle Asset Management Co., Ltd.
(ʮ̡ )
Zeng Xiaojie
(ಀወᆎ)
Hu Caiyang
(੹ජ)
Canaan China Flagship Fund Not applicable Not applicable Liang Hao
Hover4pi Fund I OFC Hover4pi Capital Management He Hui None
Global Multi Alpha Fund SP Beevest Capital Management Limited Zeng Shuzhen Zeng Shuzhen
Gaoyi Qingrui No.6 Ruixing Fund ( ৷ᆇᅅ๿ 6
ږ)
Shanghai Gaoyi Asset Management Partnership
(Limited Partnership) ( ɪऎ৷ᆇ༟ପ၍ଣΥྫ
Άุ(Υྫ ))
None None
Gaoyi Liwei Jingxuan Weishi Fund ( ৷ᆇлਃ
ږ)
Shanghai Gaoyi Asset Management Partnership
(Limited Partnership) ( ɪऎ৷ᆇ༟ପ၍ଣΥྫ
Άุ(Υྫ ))
None None
Gaoyi Renhao Long-term Value Langrun Private
Securities Investment Fund (࠽
ږ)
Shanghai Gaoyi Asset Management Partnership
(Limited Partnership) ( ɪऎ৷ᆇ༟ପ၍ଣΥྫ
Άุ(Υྫ ))
None None
Jintaiyang Gaoyi Guolu No.1 Chongyuan Fund
(˄ජ৷ᆇ਷᜼ 1 ږ)
Shanghai Gaoyi Asset Management Partnership
(Limited Partnership) ( ɪऎ৷ᆇ༟ପ၍ଣΥྫ
Άุ(Υྫ ))
None None
Gaoyi Liwei Xinshi Private Fund (ڦ
ږ)
Shanghai Gaoyi Asset Management Partnership
(Limited Partnership) ( ɪऎ৷ᆇ༟ପ၍ଣΥྫ
Άุ(Υྫ ))
None None
Gaoyi Guolu Xinyuan Private Securities
Investment Fund (Ⴣӷ෍ᗇՎҳ༟
ږ)
Shanghai Gaoyi Asset Management Partnership
(Limited Partnership) ( ɪऎ৷ᆇ༟ପ၍ଣΥྫ
Άุ(Υྫ ))
None None


--- page 28 ---
28
Name (CSI Ultimate Client) Asset Manager
UBO of Asset
Manager
UBO of CSI
Ultimate Client
Gaoyi Renhao Youxuan Zhifu Private Securities
Investment Fund (၅ӷ෍ᗇՎ
ږ)
Shanghai Gaoyi Asset Management Partnership
(Limited Partnership) ( ɪऎ৷ᆇ༟ପ၍ଣΥྫ
Άุ(Υྫ ))
None None
Gaoyi Qingrui Youxuan Ruize Private Securities
Investment Fund ( ৷ᆇᅅ๿Ꮄ፯๿ዣӷ෍ᗇՎ
ږ)
Shanghai Gaoyi Asset Management Partnership
(Limited Partnership) ( ɪऎ৷ᆇ༟ପ၍ଣΥྫ
Άุ(Υྫ ))
None None
Gaoyi Qingrui Zhenxuan Fengyuan Private
Securities Investment Fund ( ৷ᆇᅅ๿ጲ፯㋘๕
ږ)
Shanghai Gaoyi Asset Management Partnership
(Limited Partnership) ( ɪऎ৷ᆇ༟ପ၍ଣΥྫ
Άุ(Υྫ ))
None None
Gaoyi Renhao Jingxuan Chengze Private
Securities Investment Fund (ዣ
ږ)
Shanghai Gaoyi Asset Management Partnership
(Limited Partnership) ( ɪऎ৷ᆇ༟ପ၍ଣΥྫ
Άุ(Υྫ ))
None None
Gaoyi Renhao Zhenxuan Chunhe Private
Securities Investment Fund (ձ
ږ)
Shanghai Gaoyi Asset Management Partnership
(Limited Partnership) ( ɪऎ৷ᆇ༟ପ၍ଣΥྫ
Άุ(Υྫ ))
None None
Gaoyi Qingrui Jingxuan Ruixiang Convertible
Bond Multi-Strategy Private Fund ( ৷ᆇᅅ๿ၚ
ږ)
Shanghai Gaoyi Asset Management Partnership
(Limited Partnership) ( ɪऎ৷ᆇ༟ପ၍ଣΥྫ
Άุ(Υྫ ))
None None
Evolution Darwin Shangshan No.3 Private
Securities Investment Fund ( ආʷሞ༺ဧ˖ɪഛ
ږ)
Hainan Evolution Asset Management Co., Ltd.
(ʮ̡ )
Wang Yiping
(ˮɓ̻)
None
To the best of knowledge of CSI and having made all reasonable inquiries, each of the CSI Ultimate Clients and
its UBOs is an independent third party of the Company, its subsidiaries, its substantial shareholders, CSI, CLSA
and the companies which are members of the same group of companies as CLSA.


--- page 29 ---
29
DISCLAIMERS
Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the
“Stock Exchange ”) and Hong Kong Securities Clearing Company Limited ( “HKSCC ”) take no
responsibility for the contents of this announcement, make no representation as to its accuracy
or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising
from or in reliance upon the whole or any part of the contents of this announcement.
This announcement is not for release, publication, distribution, directly or indirectly, in or into
the United States (including its territories and possessions, any state of the United States and
the District of Columbia). This announcement does not constitute or form a part of any offer or
solicitation to purchase or subscribe for securities in the United States. The securities mentioned
herein have not been, and will not be, registered under the United States Securities Act of 1933,
as amended (the “U.S. Securities Act ”). The securities may not be offered or sold in the United
States except pursuant to an exemption from the registration requirements of the U.S. Securities
Act and in compliance with any applicable state securities laws, or outside the United States
unless in compliance with Regulation S under the U.S. Securities Act. There will be no public
offer of securities in the United States.
The Offer Shares are being offered and sold (1) solely to qualified institutional buyers as defined
in Rule 144A under the U.S. Securities Act pursuant to an exemption from registration under
the U.S. Securities Act and (2) outside the United States in offshore transactions in reliance on
Regulation S under the U.S. Securities Act  and applicable laws of each jurisdiction where those
offers and sales occur.
This announcement is for information purposes only and does not constitute an invitation or offer
to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential
investors should read the Prospectus dated May 5, 2026 issued by Metis TechBio Co., Ltd. ( ኒ
Ҧ(̏ԯ)ʮ̡) for detailed information about the Global Offering described below
before deciding whether or not to invest in the Shares thereby being offered.
* Potential investors of the Offer Shares should note that the Joint Sponsors and the Sponsor-Overall Coordinators
(for themselves and on behalf of the Hong Kong Underwriters), may, in their sole and absolute discretion, upon
giving notice in writing to the Company, terminate the Hong Kong Underwriting Agreement with immediate
effect upon the occurrence of any of the events set out in the section headed “Underwriting { Underwriting
Arrangements and Expenses {  Hong Kong Public Offering {  Grounds for Termination ” in the Prospectus at
any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on May 13,
2026).


--- page 30 ---
30
PUBLIC FLOAT AND FREE FLOAT
Pursuant to Rule 19A.13A of the Listing Rules, assuming that the Over-allotment Option is
not exercised, based on the Offer Price of HK$10.50 per Offer Share, the expected market
capitalization of the Company upon the Listing is HK$12,101.4 million, and the minimum
prescribed public float percentage applicable to our Shares is 15%. Immediately after the
completion of the Global Offering, 828,100,230 H Shares, representing approximately 71.85% of
the issued share capital of our Company, will count towards the public float, thereby satisfying the
minimum percentage requirement in compliance with Rule 19A.13A(1) of the Listing Rules.
Based on the Offer Price of HK$10.50 per H Share, the Company satisfies the free float
requirement under Rule 19A.13C(1)(b) of the Listing Rules.
The Directors confirm that, immediately following the completion of the Global Offering: (i) no
placee will, individually, be placed more than 10% of the enlarged issued share capital of the
Company; (ii) there will not be any new substantial Shareholder (as defined in the Listing Rules)
of the Company; (iii) the three largest public shareholders of the Company do not hold more than
50% of the H Shares in public hands at the time of the Listing in compliance with Rules 8.08(3)
and 8.24 of the Listing Rules; and (iv) there will be at least 300 Shareholders at the time of the
Listing in compliance with Rule 8.08(2) of the Listing Rules.
COMMENCEMENT OF DEALINGS
The H Share certificates will only become valid evidence of title at 8:00 a.m. on Wednesday, May
13, 2026 (Hong Kong time), provided that the Global Offering has become unconditional and the
right of termination described in the section headed “Underwriting {  Underwriting Arrangements
and Expenses {  Hong Kong Public Offering {  Grounds for Termination ” in the Prospectus has
not been exercised. Investors who trade the H Shares on the basis of publicly available allocation
details prior to the receipt of H Share certificates or prior to the H Share certificates becoming
valid evidence of title do so entirely at their own risk.
Assuming that the Global Offering becomes unconditional at or before 8:00 a.m. on Wednesday,
May 13, 2026 (Hong Kong time), it is expected that dealings in the H Shares on the Stock
Exchange will commence at 9:00 a.m. on Wednesday, May 13, 2026 (Hong Kong time). The H
Shares will be traded in board lots of 500 H Shares each, and the stock code of the H Shares will
be 7666.
By order of the Board
Metis TechBio Co., Ltd.
Tsai-Ta Lai
Chairman of the Board, executive Director and chief executive officer
Hong Kong, May 12, 2026
Directors of the Company named in the application to which this announcement relates are: (i) Dr.
Tsai-Ta Lai, Dr. Hongming Chen and Dr. Wenshou Wang as executive Directors; (ii) Mr. Hantao
Huang and Ms. Yuan Gong as non-executive Directors; and (iii) Mr. Frank Yee Chon Lyn, Dr. Jin
Li and Dr. Peter Edward Lobie as proposed independent non-executive Directors.